What is Cilgavimab and tixagevimab?
The US Food and Drug Administration has not yet approved the use of cilgavimab and/or tixagevimab. Cilgavimab, combined with tixagevimab, is an experimental medicine that's being studied to prevent COVID-19 before exposure. Cilgavimab, in combination with tixagevimab, is an experimental medicine being studied for the prevention of a before exposure. The US Food and Drug Administration has not approved the emergency use of cilgavimab combined with another medicine, tixagevimab, for prevention of COVID-19 before exposure in adults and those 12 years and older who weigh at least 40 kg (88 lbs) and are not infected.
- Who have not been exposed to COVID-19 in the past;
- The COVID-19 vaccine may not be effective for those who have moderate to severe immunosuppression and are at risk of not getting an adequate response.
- A history of severe reactions to the COID-19 vaccination may make it impossible to recommend any COVID-19 vaccination.
It is prohibited to use tixagevimab or cilgavimab on humans.
- COVID-19 treatment;
- After exposure to COVID-19, people exposed to an infected person should be treated with a COVID-19 prevention product.
Cilgavimab or tixagevimab does not replace vaccination for people who are recommended to receive COVID-19. The COVID-19 vaccine is recommended for people who could benefit. Cilgavimab or tixagevimab cannot be administered to people who have had a COVID-19 vaccination for at least two weeks. This medication guide does not list all possible uses of Cilgavimab or Tisagevimab.
Side effects of Cilgavimab and tixagevimab
If you experience any of the following symptoms of an allergic reaction, seek immediate medical attention: difficulty breathing, hives, swelling of the face, lips, or throat.
Some side effects can occur during injection. You should tell your doctor if you experience:
- The swelling of your throat or face;
- Dizziness is a feeling of light-headedness (like you could pass out);
- Shortness of breath
- Fever, chills, sweating, nausea;
- Heartbeats that are fast or slow, headaches, or pounding in the neck or ears
- Weakness, tiredness;
- Rash, or itch.
- Muscle pain.
If you experience:
- Confusion;
- A weakness
- Fast or slow heartbeats
If you experience any COVID-19 symptoms, call your doctor immediately and have yourself tested:
- Fever, chills;
- Shortness of breath;
- Tiredness;
- Aches in the muscles or body
- Headache;
- Sore throat
- Alteration in taste and smell perception
- Runny or stuffy nose
- You may experience nausea, vomiting, or diarrhoea.
Side effects of cilgavimab or tixagevib include:
- Headache;
- Tiredness;
- Cough
There may be other side effects. Call your physician if experiencing symptoms. To report side effects to the FDA call: 1-800-FDA-1088
Warnings
The US Food and Drug Administration has not yet approved the use of cilgavimab and/or tixagevimab.
Before you take this drug
If you have an allergy to polysorbate 80, cilgavimab, or tixagevimab, then it is best not to use these products.
Tell your doctor if:
- You had the COVID-19 vaccination.
- You have heart disease.
- You have a coagulation problem or thrombocytopenia.
- You are pregnant or nursing.
- You have a serious or chronic illness.
COVID-19 can cause serious illness and even death in pregnant women. Although not all risks have been identified, being treated with cilgavimab or tixagevimab may be less harmful than contracting COVID-19 while pregnant.
How to take Cilgavimab and tixagevimab?
Two separate injections of tixagevimab and cilgavimab into the muscle are given by a healthcare professional. After six months, Cilgavimab or Tisagevimab may be administered. If your doctor recommends a second dose, follow his instructions. The doctor will monitor you for at least an hour to ensure that you are not allergic. Treatment with cilgavimab or tixagevimab does not reduce your contagiousness to others. Continue using infection prevention methods, such as social isolation, hand washing, wearing protective face covers, disinfecting surfaces that you touch frequently, and not sharing personal belongings with others. Cilgavimab and tixagevimab are still under study, and the full risks of these drugs are not known.
What happens if I miss the dose?
Cilgavimab and tixagevimab are given in two separate injections. There is no daily schedule for the administration of cilgavimab.
What happens if I overdose?
In a medical environment, an overdose is treated immediately.
What should be avoided?
If your doctor prescribes any restrictions regarding food, beverage, or activity, follow their instructions.
Interaction with other drug
Other drugs, such as vitamins and herbal products, may also affect cilgavimab or tixagevib. Inform your doctor of all the other medications you take.
